REVO

meerecompany participates in a series of international symposiums,

"spurring advancement toward global markets"

- Transfer of clinical experience of Revo-i and recent knowledge with surgery demonstration of a live, high-difficult prostatectomy

- Director Kong Hyon Song of the Robotic Surgery Center of the Korea Cancer Center Hospital and Dr. Zarif from Uzbekistan participated as speakers

meerecompany (CEO Joon Koo Kim) said on the 30th that it had participated in a series of major symposiums of global urologists and shown the power of the "Revo-i" technology, speeding its advancement toward global markets.

meerecompany has recently participated in the "43rd Société Internationale d'Urologie (SIU) Symposium," one of the world's largest urology symposiums, and the "5th Mediterranean Minimally Invasive Surgery in Urology (MMISU) Symposium" that is held for countries around the Mediterranean Sea. It provided a demonstration and lecture with a live surgery using Revo-i, which drew a great response.

Firstly, in SIU that was held last month from the 11th to 14th, Director Kong Hyon Song of the Robotic Surgery Center in the Korea Cancer Center Hospital provided a presentation about a semi-live surgery that showed a video of radical prostatectomy. The realistic demonstration of the successful process of the high-difficulty surgery created a stage for deep discussion among attendees regarding robotic surgery know-how, current operation of the Robotic Surgery Center, etc.

Secondly, in MMISU that was held from November 8th to 10th, Dr. Zarifkhoja BaKhadirkhanov, Republican Specialized Scienti­fic-Practical Medical Center of Urology in Uzbekistan, performed a live surgery.

On the 9th, Dr. Zarif's robotic surgery team performing radical prostatectomy using Revo-i was streamed in real time to the symposium venue, which drew a great response from medical professionals from various countries, including Egypt, Libya, and Tunisia.

"Urological surgery is one of high-difficulty surgeries. It is an application that can make the most of the strengths of robotic surgery, and it is a representative application where Revo-i is being stably adopted," said Ho Kun Lee, Executive Vice President and Head of Surgical Robot Division of meerecompany.

Revo-i is the first domestically developed surgery robot, and it has achieved success in commercialization. It provides capability of assisting with sophisticated surgery since it supports detailed motions based on a high-resolution 3D stereoscopic image, wide view, and multi-joint devices. It has demonstrated its global competitiveness, with 1,000 cumulative cases of surgery achieved in September.